艾昆纬

IQVIA: JP Morgan Downgrades to Overweight, PT Lowered to $225.

UBS Maintains Buy Rating on IQVIA, Lowers PT to $240 from $280.

Citigroup

Citigroup lowers IQVIA PT to $200, maintains Neutral rating.

IQVIA PT Lowered to $255, Jefferies Maintains Buy Rating

IQVIA's 15min chart indicates KDJ Golden Cross and Bullish Marubozu signal.

Catalyst<ul> <li>Strong cash reserves relative to market value indicate solid financial health for IQV.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals such as RSI Overbought and MACD Death Cross dominate recent technical analysis for IQV.</li> <li>Analyst ratings show differences with only one Strong Buy and one Neutral, indicating mixed institutional sentiment.</li> <li>Recent fundamentals show negative factors including declining earnings per share year over year.</li> <li>Fund flows show negative overall trends, with large and extra-large orders contributing to outflows.</li></ul>

Key Factors

IQVIA posted Q4 2025 revenue of $4.36 billion and adjusted EPS of $3.42, both exceeding analyst expectations. IQVIA's 2026 guidance of $12.55 to $12.85 adjusted EPS fell short of the analyst consensus of $12.95, triggering a stock price decline. IQVIA's shares fell below their 200-day moving average and closed at $185.35, reflecting an 8.8% decline in trading. IQVIA generated $2.1 billion in free cash flow for 2025 and reported $16.31 billion in full-year revenue.

IQV News